Mumbai, 28th April 2026: Vivekanand Education Society’s College of Pharmacy (VESCOP), in collaboration with ENTOD Pharmaceuticals and Association of Pharmacy Teachers of India – Maharashtra State Branch, hosted Vision 360: Translating Ophthalmic Innovations from Bench to Bedside’, a national symposium focused on bridging the gap between laboratory research and real-world clinical application in ophthalmology.
Held at VESCOP, the symposium addressed the rising burden of eye disorders such as glaucoma, diabetic retinopathy, and ocular infections, while emphasizing the need for stronger translational approaches in ophthalmic care. The event featured expert-led sessions by leading voices in the field. Prof. Sadhana Sathaye, Professor, DPST, ICT Matunga, spoke on novel ocular formulations using Saraca asoca for cataract and dry eye management. Dr. Kasturi Bhadsavle, Founder of The Eye Vet, shared perspectives on ophthalmic drug delivery in veterinary practice. At the same time, Dr. Sanjay Tamoli, Founder and Director, TIMER, highlighted clinical research approaches for cataract treatment and prevention. Prof. Thakur Raghu Raj Singh, Chair of Pharmaceutics & Founder of Re-Vana Therapeutics at Queen’s University Belfast, discussed recent innovations and challenges in ophthalmic drug delivery.
The symposium brought together researchers, clinicians, pharmaceutical leaders, and students, fostering meaningful dialogue on improving access, innovation, and clinical outcomes in eye care. The conference also featured 22 research posters aligning with the theme, offering a valuable platform for students and researchers to present their work and exchange ideas.
Prof. Supriya Shidhaye, Principal, VESCOP, said, “Through Vision 360, we are creating a dynamic platform that brings together diverse stakeholders from academia, industry, and clinical practice. The future of ophthalmic care depends on how effectively we can translate research into real-world applications. Initiatives like these not only encourage knowledge exchange but also inspire innovation that is impactful, scalable, and aligned with the evolving needs of healthcare.”
Shri. Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, added, “With rapid advancements in ophthalmic research, it is essential to strengthen the translation of innovation from bench to bedside. Vision 360 provides a vital platform for academia, clinicians, and industry to collaborate and drive progress in ophthalmic therapeutics.”
The symposium brought together researchers, clinicians, pharmaceutical leaders, and students, fostering meaningful dialogue on improving access, innovation, and clinical outcomes in eye care. With a significant proportion of vision impairment being preventable, the event reinforced the importance of collaborative efforts to translate scientific advancements into effective patient care.
About Vivekanand Education Society
Established in 1962, Vivekanand Education Society (VES) is committed to nurturing excellence in academics, innovation, and holistic development. Located in Chembur, Mumbai, VES has grown into 7 sprawling campuses with 26+ institutions offering education across diverse fields such as arts, commerce, science, engineering, law, management, architecture, business school and more.
Guided by the values of Swami Vivekananda and the visionary leadership of Shri Hashu Advani Ji, VES strives to create future-ready individuals who excel in their fields while embodying ethical values and social responsibility. With state-of-the-art facilities, a dedicated faculty, and a vibrant student community, VES continues to inspire generations to achieve their highest potential.
About ENTOD Pharmaceuticals
ENTOD Pharmaceuticals is a leading international, research-driven pharmaceutical company with over four decades of specialized expertise in ophthalmic, ENT, and dermatological medicine. With a product portfolio exceeding 300 formulations, a workforce of 2,000+ professionals, and a commercial presence in 67+ countries, ENTOD is globally synonymous with innovation in specialty pharma. Their therapeutic portfolio spans dry eyes, digital eye strain, glaucoma, ocular infections, post-cataract and post-LASIK medication, and beyond.
